(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 December 2021 (02.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/243002 A1

(51) International Patent Classification:
C07K 16/40 (2006.01)

(21) International Application Number:
PCT/US2021/034489

(22) International Filing Date:
27 May 2021 (27.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/032,451 29 May 2020 (29.05.2020) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320 (US).


(72) Inventors: **HAMER, Andrew W.**; c/o Amgen Inc., One Amgen Center Drive Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320 (US). **BRIDGES, Ian Matthew**; c/o Amgen Inc., One Amgen Center Drive Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320 (US). **WANG, Huei**; c/o Amgen Inc., One Amgen Center Drive Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320 (US). **RUZZA, Andrea**; c/o Amgen Inc., One Amgen Center Drive Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320 (US). **KURTZ, Christopher**; c/o Amgen Inc., One Amgen Center Drive Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320 (US).

(74) Agent: **FULLER, Michael L.**; KNOBBE MARTENS OLSON & BEAR LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PCSK9 INHIBITORS AND METHODS OF USE THEREOF TO TREAT CHOLESTEROL-RELATED DISORDERS



(57) Abstract: Methods of lowering LDL cholesterol in a pediatric subject having a cholesterol-related disorder, e.g., heterozygous familial hypercholesterolemia (HeFH), by administering a PCSK9 inhibitor are provided.

WO 2021/243002 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*